Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of “Buy” by Brokerages

Rapport Therapeutics, Inc. (NASDAQ:RAPP) has been given a consensus rating of “Buy” by the thirteen analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $62.8571.

Several brokerages recently commented on RAPP. UBS Group reiterated a “strong-buy” rating on shares of Rapport Therapeutics in a report on Monday, August 17th. HC Wainwright raised their price objective on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Raymond James Financial restated a “strong-buy” rating and set a $75.00 target price on shares of Rapport Therapeutics in a research report on Monday, August 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $65.00 target price on shares of Rapport Therapeutics in a research note on Wednesday, August 19th.

Insider Transactions at Rapport Therapeutics

In related news, CEO Abraham Ceesay sold 28,958 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the completion of the transaction, the chief executive officer owned 486,108 shares in the company, valued at $23,338,045.08. The trade was a 5.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 73,034 shares of company stock worth $3,484,157. 12.48% of the stock is owned by insiders.

Institutional Trading of Rapport Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV bought a new stake in shares of Rapport Therapeutics during the first quarter worth $30,000. Meeder Asset Management Inc. purchased a new stake in shares of Rapport Therapeutics during the fourth quarter valued at $37,000. Russell Investments Group Ltd. bought a new position in shares of Rapport Therapeutics in the third quarter worth about $43,000. State of Wyoming bought a new position in shares of Rapport Therapeutics in the second quarter worth about $65,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after buying an additional 4,582 shares during the period.

Rapport Therapeutics Stock Down 0.2%

NASDAQ RAPP opened at $48.67 on Tuesday. Rapport Therapeutics has a 52 week low of $14.11 and a 52 week high of $52.93. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -16.01 and a beta of 0.97. The company has a fifty day moving average of $43.61 and a two-hundred day moving average of $37.08.

Rapport Therapeutics (NASDAQ:RAPP) last announced its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Equities research analysts anticipate that Rapport Therapeutics will post -4.09 EPS for the current year.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.